AngioDynamics shares are trading lower after the company reported Q1 financial results. The company reported a year-over-year decrease in its AngioVac sales.

AngioDynamics Announces Publication of DIRECT Study Results and New Category I CPT Code for Pancreatic IRE

AngioDynamics reported the publication of findings from its DIRECT study and the establishment of a new Category I CPT code for pancreatic irreversible electroporation (IRE).

AngioDynamics Says Humana Updates Medicare Advantage Policy To Cover NanoKnife For Eligible Prostate And Liver Cancer Patients, Effective October 1

HC Wainwright & Co. Maintains Buy on AngioDynamics, Lowers Price Target to $18

ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y

AngioDynamics (ANGO) reported Q1 FY2027 adjusted loss of 4 cents per share, beating estimates by 60%, with revenues up 6.9% to $80.9 million. Med Tech revenues grew 13.2%, driven by strong performance from Auryon, AlphaVac, and NanoKnife. Gross margin expanded 410 basis points to 59.4%, though the stock fell over 20% following the announcement. The company reiterated FY2027 guidance of $336-$341 million in revenues with Med Tech expected to grow 12-15%.